Alignment Healthcare (NASDAQ:ALHC) Posts Earnings Results, Beats Estimates By $0.04 EPS

Alignment Healthcare (NASDAQ:ALHC) announced its quarterly earnings data on Thursday. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04, FiscalAI reports. Alignment Healthcare had a return on equity of 12.32% and a net margin of 0.47%.The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.22 billion. During the same period in the previous year, the business earned ($0.05) EPS. The firm’s revenue was up 33.3% compared to the same quarter last year.

Here are the key takeaways from Alignment Healthcare’s conference call:

• Membership grew ~31% YoY to 284,800, revenue rose 33% to $1.2B and Adjusted EBITDA increased 88% to $38M — results beat guidance and management raised full‑year revenue and profitability ranges.
• Management highlighted material operational progress — claims auto‑adjudication improved from <15% to >60% YTD — and is investing in AI, contract automation and talent to drive further scale and margin expansion.
• A CMS rule change exposed an internal workflow error that caused the company to pay acute rates instead of observation in January (about a $2M impact that cannot be clawed back); the process was corrected by end of February.
• Full‑year and Q2 guidance incorporate higher inpatient admissions per 1,000 driven by intentional growth in higher‑acuity D‑SNP/LIS/dual members and a cautious risk‑adjustment stance for new members, with potential upside from later CMS “sweeps.”

Alignment Healthcare Stock Down 10.1%

ALHC traded down $2.28 during midday trading on Friday, reaching $20.26. 13,842,299 shares of the company were exchanged, compared to its average volume of 3,435,011. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.71 and a current ratio of 1.71. The company’s fifty day moving average price is $19.38 and its 200 day moving average price is $19.42. The company has a market cap of $4.19 billion, a price-to-earnings ratio of -2,023.98, a price-to-earnings-growth ratio of 4.62 and a beta of 1.26. Alignment Healthcare has a one year low of $11.63 and a one year high of $23.87.

Insider Activity

In other Alignment Healthcare news, CFO James M. Head sold 11,100 shares of the business’s stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $21.08, for a total transaction of $233,988.00. Following the completion of the sale, the chief financial officer directly owned 173,495 shares of the company’s stock, valued at approximately $3,657,274.60. The trade was a 6.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John E. Kao sold 82,299 shares of the business’s stock in a transaction that occurred on Monday, April 13th. The stock was sold at an average price of $20.80, for a total value of $1,711,819.20. Following the sale, the chief executive officer directly owned 1,806,641 shares of the company’s stock, valued at $37,578,132.80. This represents a 4.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,474,097 shares of company stock worth $28,679,550. Company insiders own 7.00% of the company’s stock.

Institutional Trading of Alignment Healthcare

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALHC. Wellington Management Group LLP increased its holdings in Alignment Healthcare by 167.3% during the 3rd quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock worth $193,516,000 after purchasing an additional 6,940,277 shares in the last quarter. Invesco Ltd. increased its holdings in Alignment Healthcare by 122.3% during the 2nd quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock worth $58,387,000 after purchasing an additional 2,294,739 shares in the last quarter. Loomis Sayles & Co. L P bought a new stake in Alignment Healthcare during the 4th quarter worth approximately $44,162,000. Qube Research & Technologies Ltd grew its holdings in shares of Alignment Healthcare by 269.6% in the second quarter. Qube Research & Technologies Ltd now owns 1,523,986 shares of the company’s stock valued at $21,336,000 after acquiring an additional 1,111,685 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Alignment Healthcare by 273.5% in the third quarter. Bank of America Corp DE now owns 1,412,498 shares of the company’s stock valued at $24,648,000 after acquiring an additional 1,034,273 shares in the last quarter. 86.19% of the stock is owned by institutional investors.

Trending Headlines about Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q1 beat: ALHC reported $0.05 EPS (vs. ~$0.01 consensus) and $1.24B revenue (vs. ~$1.22B), with revenue up ~33% YoY and signs of margin expansion. This validates growth execution and short-term profitability improvement. MarketBeat Q1 Results
• Positive Sentiment: Raised medium-term targets: Management forecasted $138M–$163M adjusted EBITDA for 2026 and lifted membership guidance to 294k–299k — a clear positive for longer-term revenue and margin modeling. Seeking Alpha – 2026 Adjusted EBITDA & Membership Outlook
• Positive Sentiment: Analyst upgrade: Zacks moved ALHC from “hold” to “strong-buy,” which could support demand if upgrades gather momentum. Zacks Upgrade
• Neutral Sentiment: Earnings-call details and strategy: Management discussed disciplined growth, margin initiatives and membership strategy — useful for modeling but not immediately market-moving beyond guidance. Earnings Call Transcript
• Neutral Sentiment: Pre-earnings technical setup had bullish signals (bull pennant), but technicals are secondary to the guidance-driven move. FXEmpire Technical Note
• Negative Sentiment: Market reaction: Shares fell sharply after the report (after-hours drop reported ~10%), suggesting investors were disappointed by the tone or conservatism of near-term guidance despite the beat; heavy volume indicates conviction in the sell-off. OCBJ – Shares Fall After-Hours
• Negative Sentiment: Cautious near-term guidance: Commentary and guidance nuances in analyst write-ups flagged conservatism on upcoming quarters, which likely triggered profit-taking and dampened the beat’s impact. MSN Deep Dive

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ALHC shares. UBS Group upped their price target on Alignment Healthcare from $21.00 to $22.00 and gave the stock a “neutral” rating in a research note on Friday. TD Cowen upped their price target on Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Wall Street Zen downgraded Alignment Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Robert W. Baird set a $28.00 price target on Alignment Healthcare in a research note on Friday, January 30th. Finally, JPMorgan Chase & Co. upped their price target on Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $24.89.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.